Antibody-mediated immunity to SARS-CoV-2 spike

John M. Errico, Lucas J. Adams, Daved H. Fremont

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

1 Scopus citations


Despite effective spike-based vaccines and monoclonal antibodies, the SARS-CoV-2 pandemic continues more than two and a half years post-onset. Relentless investigation has outlined a causative dynamic between host-derived antibodies and reciprocal viral subversion. Integration of this paradigm into the architecture of next generation antiviral strategies, predicated on a foundational understanding of the virology and immunology of SARS-CoV-2, will be critical for success. This review aims to serve as a primer on the immunity endowed by antibodies targeting SARS-CoV-2 spike protein through a structural perspective. We begin by introducing the structure and function of spike, polyclonal immunity to SARS-CoV-2 spike, and the emergence of major SARS-CoV-2 variants that evade immunity. The remainder of the article comprises an in-depth dissection of all major epitopes on SARS-CoV-2 spike in molecular detail, with emphasis on the origins, neutralizing potency, mechanisms of action, cross-reactivity, and variant resistance of representative monoclonal antibodies to each epitope.

Original languageEnglish
Title of host publicationAdvances in Immunology
PublisherAcademic Press Inc.
StateAccepted/In press - 2022

Publication series

NameAdvances in Immunology
ISSN (Print)0065-2776
ISSN (Electronic)1557-8445


  • Coronavirus cross-reactivity
  • N-terminal domain antibody
  • Neutralizing variants of concern
  • Receptor-binding domain antibody
  • S2 antibody
  • SARS-CoV-2 neutralizing antibody
  • SARS-CoV-2 spike antibody
  • Spike epitopes


Dive into the research topics of 'Antibody-mediated immunity to SARS-CoV-2 spike'. Together they form a unique fingerprint.

Cite this